The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG.
 
Jin-Ji Yang
No Relationships to Disclose
 
Yan Zhang
No Relationships to Disclose
 
Lin Wu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Hengrui Medicine; Innovate Biopharmaceuticals; Lilly; MSD; Pfizer; Roche China
 
Jie Hu
No Relationships to Disclose
 
Zhe-Hai Wang
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Jing-Hua Chen
No Relationships to Disclose
 
Yun Fan
No Relationships to Disclose
 
Gen Lin
No Relationships to Disclose
 
Qiming Wang
No Relationships to Disclose
 
Yu Yao
No Relationships to Disclose
 
Jun Zhao
No Relationships to Disclose
 
Yuan Chen
No Relationships to Disclose
 
Jian Fang
No Relationships to Disclose
 
Yong Song
No Relationships to Disclose
 
Wei Zhang
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Ren-Hua Guo
No Relationships to Disclose
 
XingYa Li
No Relationships to Disclose
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)